PF-07985045 + gemcitabine + nab-paclitaxel

PF-07985045 + gemcitabine + nab-paclitaxel is a pharmaceutical drug combination currently under investigation in clinical trials for advanced solid tumors, including pancreatic ductal adenocarcinoma and other KRAS-mutant cancers[1][3][4][5]. PF-07985045 is an oral small molecule inhibitor targeting the KRAS pathway, aiming to block KRAS-driven signaling responsible for tumor cell proliferation and survival[2][6]. Gemcitabine is a nucleoside analog antimetabolite that inhibits DNA synthesis, leading to apoptosis in rapidly dividing cells. Nab-paclitaxel is an albumin-bound formulation of paclitaxel, a microtubule inhibitor causing mitotic arrest and cell death. The combination seeks to leverage targeted KRAS inhibition (PF-07985045) alongside cytotoxic chemotherapy (gemcitabine, nab-paclitaxel) for synergistic anti-tumor effects primarily in first-line metastatic pancreatic cancer patients, but also in other solid tumors with KRAS mutations[3][5].

Other names

pan-KRAS inhibitor PF-07985045